Alpha-glucosidase Inhibitors Market Analysis

Indication (Type 2 Diabetes Mellitus, Pre-diabetes)

Type 2 diabetes mellitus segment is estimated to account for more than 89.5% alpha-glucosidase inhibitors market share by the end of 2037. The increasing prevalence of type 2 diabetes mellitus globally creates a substantial population in need of effective management solutions. For instance, the prevalence of type 2 diabetes mellitus among older adults accounted for 96% in 2021. As per the analysis by the World Health Organization (WHO), around 95% of people living with diabetes have type 2 diabetes. Alpha-glucosidase inhibitors specifically target postprandial blood sugar levels, making them valuable for managing the unique challenges faced by type 2 diabetes patients.

Drug Type (Acarbose, Miglitol, Voglibose, Combination Drugs)

The acarbose drug type segment in alpha-glucosidase inhibitors market is foreseen to hold a dominant revenue share through 2037 owing to its effectiveness in the treatment of diabetes. Acarbose has a proven track record in effectively managing postprandial blood glucose levels, making it a trusted choice among healthcare providers. The drug is often included in diabetes management guidelines, which supports its continued use in clinical practice and drives demand.

Acarbose has strong brand recognition and is marketed under various names, such as Glucobay in Europe and Asia, Precose in the U.S., and Prandase in Canada. Moreover, Acarbose is frequently used in combination with other antidiabetic medications, further enhancing its effectiveness and broadening its use among patients.

Our in-depth analysis of the global market includes the following segments: